P636: A FIRST-IN-HUMAN PHASE 1 STUDY OF ORAL LOXO-338, A SELECTIVE BCL2 INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES by Michal Kwiatek, Guru Subramanian Guru Murthy, Marc Hoffmann, Lindsey Roeker, Benoit Tessoulin, Alexey Danilov, Alvaro J. Alencar, Nirav N. Shah, Herve Ghesquieres, Steven Le Gouill, Wojciech Jurczak, Anthony R. Mato, Vishalkumar Patel, Yingying Guo-Avrutin, James M. Pauff, Maciej Kazmierczak

Get full text